32959058Hoff FW, van Dijk AD, Qiu Y, Ruvolo PP, Gerbing RB, Leonti AR, Jenkins GN, Gamis AS, Aplenc R, Kolb EA, Alonzo TA, Meshinchi S, de Bont ESJM, Bruggeman SWM, Kornblau SM, Horton TMBloodAntineoplastic Agents; Bortezomib; Heat Shock Transcription Factors; Leukemia, Myeloid, AcuteChild; Child, Preschool; Drug Resistance, Neoplasm; Female; Humans; Infant; Male; Point Mutation; Prognosis; TranscriptomeHoff FW, van Dijk AD, Qiu Y, Ruvolo PP, Gerbing RB, Leonti AR, Jenkins GN, Gamis AS, Aplenc R, Kolb EA, Alonzo TA, Meshinchi S, de Bont ESJM, Bruggeman SWM, Kornblau SM, Horton TM. Heat shock factor 1 (HSF1-pSer326) predicts response to bortezomib-containing chemotherapy in pediatric AML: a COG report. Blood. 2021 02 25; 137(8):1050-1060.Blood2021-02-25T00:00:002021Heat shock factor 1 (HSF1-pSer326) predicts response to bortezomib-containing chemotherapy in pediatric AML: a COG report.cmhprofilesont:personsuffixperson suffixprns:fullNamefull nameprns:hasAuthorListauthor listprns:hasNetworkhas networkprns:hasPublicationVenuepublished inprns:hasSubjectAreaMajorTopicListhas major subject area listprns:hasSubjectAreaMinorTopicListhas minor subject area listprns:informationResourceReferenceinformation resource referenceprns:isPrimaryPositionis primary positionprns:latitudelatitudeprns:longitudelongitudeprns:mainImagephotoprns:maxWeightmaximum weightprns:medlineTAjournal title abbreviationprns:meshDescriptorUIMeSH DescriptorUIprns:meshSemanticGroupNameMeSH semantic group nameprns:minWeightminimum weightprns:numberOfAuthorsnumber of authorsprns:numberOfConnectionsnumber of connectionsprns:numberOfPublicationsnumber of publicationsprns:personIdPerson IDprns:personInPrimaryPositionperson in primary positionprns:positionInDepartmentposition in departmentprns:positionInDivisionposition in divisionprns:predicateNodepredicate nodeprns:publicationDatepublication dateprns:sortOrdersort orderprns:uniquenessWeightuniqueness weightprns:yearyearAcademic ArticleArticleDocumentbibo:pmidPubMed Identifiervivo:authorRankauthor rank in publicationAuthorshipDepartmentDivisionvivo:hasSubjectAreahas subject areavivo:hrJobTitleHR job titleInformation Resourcevivo:informationResourceInAuthorshipauthorsvivo:linkedAuthorlinked authorvivo:linkedInformationResourcelinked information resourcevivo:orcidIdORCID idPositionvivo:positionInOrganizationposition in organizationvivo:preferredTitlepreferred titlerdf:predicatepredicaterdf:typetyperdfs:labellabelConceptAgentfoaf:firstNamefirst namefoaf:lastNamelast nameOrganizationPersonD008297Physiology11633280.54802MaleD011379Procedures582130.938284PrognosisD015470Disorders81140.899415Leukemia, Myeloid, AcuteD017354Physiology440.998573Point MutationD019008Physiology10270.975384Drug Resistance, NeoplasmMD, MPHAlanGamisAlan S. Gamis0.000000000000000.0000000000000049Gamis, Alan0000-0003-1513-2893Chief, Section of OncologyD0000692863100.995457BortezomibD059467Concepts & IdeasGenes & Molecular Sequences17520.955131TranscriptomePediatricsClinicalChildren's Mercy Kansas CityAuthorship 792180.2019770.2019771authors10.2513has subject areaD000970Chemicals & Drugs20570.947703Antineoplastic Agentstrue1Chief, Section of OncologyChief, Section of OncologyD002648Living Beings11632570.520082ChildD002675Living Beings10415030.693171Child, PreschoolD005260Physiology11835990.534568FemaleD006801Living Beings12067970.397999HumansD007223Living Beings9914490.693714Infant